What is the recommended sublingual dosing schedule of atropine sulfate 1% ophthalmic solution for an adult patient on clozapine who develops bothersome hypersalivation?

Atropine Drops Should NOT Be Used for Clozapine-Induced Hypersalivation Due to Lethal Overdose Risk

The most recent and authoritative 2026 Lancet Psychiatry consensus guidelines explicitly warn that atropine sublingual drops can be lethal in overdose and should be avoided for clozapine-induced sialorrhea. 111 Instead, ipratropium sublingual spray and amisulpride are recommended as safer pharmacological alternatives with low rates of adverse drug reactions.

Why Atropine Is Not Recommended

The 2026 global Delphi panel consensus guidelines from The Lancet Psychiatry specifically caution against atropine drops for this indication, citing:

• Lethality in overdose - a critical safety concern given the psychiatric population and potential for accidental or intentional overdose 111
• Increased constipation risk - particularly problematic since clozapine already causes severe gastrointestinal hypomotility, with ileus being the leading cause of clozapine-associated death 11

Recommended Alternatives (in order of preference)

First-Line Non-Pharmacological Approaches

• Chewing sugar-free gum
• Placing a towel over the pillow when sleeping 11

Preferred Pharmacological Options

1. Ipratropium sublingual spray - low adverse drug reaction profile 111
2. Amisulpride augmentation - low adverse drug reaction profile 111

Agents to Avoid

• Atropine sublingual drops (lethal in overdose)
• Hyoscine lozenges (increases constipation)
• Diphenhydramine (increases constipation) 111

Critical Safety Context

The FDA labeling for atropine ophthalmic solution confirms significant systemic absorption (64% bioavailability) when used topically 2, and the fatal pediatric and adult doses are unknown 2. The ophthalmic formulation is not approved for sublingual use 22, and off-label sublingual administration carries substantial risk in patients already vulnerable to anticholinergic toxicity.

If Atropine Were to Be Used Despite Guidelines (Not Recommended)

Research literature describes off-label dosing of 1-2 drops of 1% atropine ophthalmic solution sublingually, 2-3 times daily 3, with one RCT using a single 600 μg dose 4. However, this contradicts current best-practice guidelines and poses unacceptable mortality risk. A 2024 case report documented efficacy but discontinuation due to tachycardia and overdose concerns 5.

The evidence hierarchy clearly prioritizes safety: While older research studies (2019-2024) 36478 demonstrate atropine's efficacy for hypersalivation, the most recent 2026 expert consensus guidelines explicitly recommend against its use due to mortality concerns, superseding earlier efficacy data.